AstraZeneca Boosts Rare Diseases Portfolio with Acquisition of Amolyt Pharma

AstraZeneca has announced a definitive plan on Thursday, March 14 to acquire Amolyt Pharma, a clinical-stage biotechnology company which focuses on rare endocrine diseases, for $1.05B. The deal, which includes $800M upfront and the potential for another $250M upon meeting regulatory milestones, is expected to close in the third quarter. Three years after acquiring Alexion, the acquisition of Amolyt Pharma will boost the Alexion, Astrazeneca Rare Disease pipeline with the addition of eneboparatide (AZP-3601), a drug currently in Phase 3 testing with a novel mechanism designed to meet key therapeutic goals of hypoparathyroidism. Hypoparathyroidism, which is one of the largest known rare diseases, impacts approximately 115,000 people in the United States and 107,000 in the European Union, 80% of which are women.

To read more, click here.

[Source: AstraZeneca, March 14th, 2024]